摘要
目的:评价参附注射液对晚期前列腺癌患者血清前列腺特异抗原(Prostate Specific Antigen,PSA)水平及生存质量的影响。方法:60例前列腺癌患者,分成观察组和对照组。对照组:给予常规治疗。观察组:在常规治疗的基础上,加用参附注射液治疗。结果:治疗后,两组前列腺癌患者的身体状况、功能状况等评分均有显著改善,差异具有统计学意义(P<0.05);治疗后,观察组前列腺癌患者的身体状况、功能状况等评分均优于对照组,差异具有统计学意义(P<0.05)。治疗后,两组前列腺癌患者血清PSA水平均有显著改善,差异具有统计学意义(P<0.01);治疗后,观察组前列腺癌患者血清PSA水平低于对照组,差异具有统计学意义(P<0.01)。结论:参附注射液治疗晚期前列腺癌患者具有较佳疗效,能有效改善患者的血清PSA水平及生存质量。
Objective ： To evaluate the effect of Shenfu Injection on serum prostate specific antigen （PSA） level and quality of life of patients with advanced prostate cancer. Method：60 cases of prostate cancer patients were divided into the observation group and the control group. Control group used the routine treatment. The observation group on the basis of conventional therapy combined with Shenfu Injection. Results ： After treatment, scores of health and functional status of two groups were improved significantly, and the difference was statistically significant （P 〈 0.05 ）. The observation group was better than the control group, and the difference was statistically significant （P 〈 0.05 ）. The serum level of PSA of both two groups was improved significantly,and the difference was statistically significant （P 〈0.01 ）. The serum level of PSA in the observation group was less than that in the control group, and the difference was statistically significant （P 〈 0.01 ）. Conclusion ： Shenfu Injection in the treatment of patients with advanced prostate cancer has the good curative effect, and can improve the serum PSA level and the quality of life of patients.
出处
《中华中医药学刊》
CAS
2014年第6期1459-1461,共3页
Chinese Archives of Traditional Chinese Medicine
基金
湖州市科技计划项目(2012YSB25)
关键词
参附注射液
前列腺癌
血清
前列腺特异抗原
生存质量
Shenfu Injection
prostate cancer
serum
prostate specific antigen
quality of life
